{"id":"https://openalex.org/W2095825832","doi":"https://doi.org/10.1128/aac.00409-12","title":"Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load","display_name":"Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load","publication_year":2012,"publication_date":"2012-05-22","ids":{"openalex":"https://openalex.org/W2095825832","doi":"https://doi.org/10.1128/aac.00409-12","mag":"2095825832","pmid":"https://pubmed.ncbi.nlm.nih.gov/22615275","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3421589"},"language":"en","primary_location":{"id":"doi:10.1128/aac.00409-12","doi":"https://doi.org/10.1128/aac.00409-12","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.00409-12","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://europepmc.org/articles/PMC3421589","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026242578","display_name":"Victor G. Kramer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Victor G. Kramer","raw_affiliation_strings":["Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada","McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054825542","display_name":"Susan M. Schader","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Susan M. Schader","raw_affiliation_strings":["Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111799571","display_name":"Maureen Oliveira","orcid":"https://orcid.org/0000-0002-3537-9474","observed_orcids":["https://orcid.org/0000-0002-3537-9474"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Maureen Oliveira","raw_affiliation_strings":["McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027596556","display_name":"Susan P. Colby-Germinario","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Susan P. Colby-Germinario","raw_affiliation_strings":["McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087199371","display_name":"Daniel Aaron Donahue","orcid":"https://orcid.org/0000-0003-2120-4697","observed_orcids":["https://orcid.org/0000-0003-2120-4697"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Daniel A. Donahue","raw_affiliation_strings":["Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016805122","display_name":"Diane N. Singhroy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Diane N. Singhroy","raw_affiliation_strings":["Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014694684","display_name":"Randy Tressler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1280259254","display_name":"Henry M. Jackson Foundation","ror":"https://ror.org/04q9tew83","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1280259254"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randy Tressler","raw_affiliation_strings":["Henry M. Jackson Foundation, Rockville, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Henry M. Jackson Foundation, Rockville, Maryland, USA","institution_ids":["https://openalex.org/I1280259254"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053217452","display_name":"Richard D. Sloan","orcid":"https://orcid.org/0000-0002-8973-1971","observed_orcids":["https://orcid.org/0000-0002-8973-1971"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Richard D. Sloan","raw_affiliation_strings":["McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029881635","display_name":"Mark A. Wainberg","orcid":"https://orcid.org/0000-0002-0272-1317","observed_orcids":["https://orcid.org/0000-0002-0272-1317"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405267356","display_name":"Lady Davis Institute for Medical Research","ror":"https://ror.org/02c1np254","country_code":"CA","type":"education","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405267356","https://openalex.org/I4405279980"]},{"id":"https://openalex.org/I4405287669","display_name":"Mark Wainberg Centre for Viral Diseases","ror":"https://ror.org/05v3dkd06","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4405287669","https://openalex.org/I5023651"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Mark A. Wainberg","raw_affiliation_strings":["Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada","Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I5023651"]},{"raw_affiliation_string":"McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada","institution_ids":["https://openalex.org/I2801824472","https://openalex.org/I4405267356","https://openalex.org/I4405287669"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.0269,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.93970303,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"56","issue":"8","first_page":"4154","last_page":"4160"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.6327999830245972,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.6327999830245972,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.36329999566078186,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/maraviroc","display_name":"maraviroc","score":0.8980000019073486},{"id":"https://openalex.org/keywords/hiv-1-entry-inhibitors","display_name":"HIV-1 entry inhibitors","score":0.9660000205039978},{"id":"https://openalex.org/keywords/viral-load-quantification","display_name":"viral load quantification","score":0.6840000152587891},{"id":"https://openalex.org/keywords/ccr5-tropic-hiv-1","display_name":"CCR5-tropic HIV-1","score":0.8709999918937683},{"id":"https://openalex.org/keywords/cxcr4-tropic-hiv-1","display_name":"CXCR4-tropic HIV-1","score":0.9950000047683716},{"id":"https://openalex.org/keywords/dual-tropic-hiv-1","display_name":"dual-tropic HIV-1","score":0.9539999961853027},{"id":"https://openalex.org/keywords/efavirenz","display_name":"efavirenz","score":0.8240000009536743},{"id":"https://openalex.org/keywords/raltegravir","display_name":"raltegravir","score":0.9950000047683716},{"id":"https://openalex.org/keywords/enfuvirtide","display_name":"enfuvirtide","score":0.9929999709129333},{"id":"https://openalex.org/keywords/amd3100","display_name":"AMD3100","score":0.9789999723434448},{"id":"https://openalex.org/keywords/antiretroviral-drugs","display_name":"antiretroviral drugs","score":0.7839999794960022},{"id":"https://openalex.org/keywords/plasma-viral-load","display_name":"plasma viral load","score":0.5680000185966492},{"id":"https://openalex.org/keywords/tzm-bl-cells","display_name":"TZM-bl cells","score":0.75}],"concepts":[{"id":"https://openalex.org/C2778899366","wikidata":"https://www.wikidata.org/wiki/Q421369","display_name":"Maraviroc","level":3,"score":0.8447432518005371},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.8308078050613403},{"id":"https://openalex.org/C58475186","wikidata":"https://www.wikidata.org/wiki/Q4118894","display_name":"Viral entry","level":4,"score":0.784244954586029},{"id":"https://openalex.org/C106358424","wikidata":"https://www.wikidata.org/wiki/Q1662346","display_name":"Infectivity","level":3,"score":0.7369948029518127},{"id":"https://openalex.org/C2778037500","wikidata":"https://www.wikidata.org/wiki/Q423327","display_name":"Enfuvirtide","level":5,"score":0.6820691227912903},{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.6621050834655762},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.6020103693008423},{"id":"https://openalex.org/C2776997796","wikidata":"https://www.wikidata.org/wiki/Q1345259","display_name":"Entry inhibitor","level":5,"score":0.548216700553894},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.46307265758514404},{"id":"https://openalex.org/C37044404","wikidata":"https://www.wikidata.org/wiki/Q5009692","display_name":"CCR5 receptor antagonist","level":5,"score":0.45507800579071045},{"id":"https://openalex.org/C28406088","wikidata":"https://www.wikidata.org/wiki/Q5571762","display_name":"Extracellular","level":2,"score":0.452933132648468},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.45211589336395264},{"id":"https://openalex.org/C79879829","wikidata":"https://www.wikidata.org/wiki/Q5571762","display_name":"Intracellular","level":2,"score":0.4421008229255676},{"id":"https://openalex.org/C156719811","wikidata":"https://www.wikidata.org/wiki/Q28774","display_name":"Reverse transcriptase","level":4,"score":0.4231230318546295},{"id":"https://openalex.org/C2780404665","wikidata":"https://www.wikidata.org/wiki/Q421552","display_name":"Raltegravir","level":5,"score":0.41203194856643677},{"id":"https://openalex.org/C140704245","wikidata":"https://www.wikidata.org/wiki/Q3933202","display_name":"Viral replication","level":3,"score":0.373892605304718},{"id":"https://openalex.org/C2776258796","wikidata":"https://www.wikidata.org/wiki/Q5590520","display_name":"Gp41","level":4,"score":0.2458687722682953},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21494540572166443},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.1609976589679718},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.11967059969902039},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1146797239780426},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.10121732950210571},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.08713865280151367},{"id":"https://openalex.org/C12823836","wikidata":"https://www.wikidata.org/wiki/Q24720618","display_name":"Chemokine receptor","level":4,"score":0.07188335061073303},{"id":"https://openalex.org/C67705224","wikidata":"https://www.wikidata.org/wiki/Q11053","display_name":"RNA","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.0},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000068898","descriptor_name":"Raltegravir Potassium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077560","descriptor_name":"Enfuvirtide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077592","descriptor_name":"Maraviroc","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000080027","descriptor_name":"Cyclams","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000480","descriptor_name":"Alkynes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001596","descriptor_name":"Benzylamines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004279","descriptor_name":"DNA, Viral","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006571","descriptor_name":"Heterocyclic Compounds","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015700","descriptor_name":"HIV Envelope Protein gp41","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D019713","descriptor_name":"Receptors, CCR5","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019718","descriptor_name":"Receptors, CXCR4","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D048588","descriptor_name":"Benzoxazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D053586","descriptor_name":"Virus Internalization","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D054303","descriptor_name":"HIV Reverse Transcriptase","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1128/aac.00409-12","doi":"https://doi.org/10.1128/aac.00409-12","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.00409-12","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2560009","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3421589","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3421589","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3421589","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:22615275","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22615275","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.902.4622","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.902.4622","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://aac.asm.org/content/56/8/4154.full.pdf","raw_type":"text"},{"id":"mag:2343381749","doi":null,"is_oa":false,"landing_page_url":"https://www.researchgate.net/profile/Susan_Schader2/publication/225037597_Maraviroc_and_Other_HIV-1_Entry_Inhibitors_Exhibit_a_Class-_1_Specific_Redistribution_Effect_that_Results_in_Increased_2_Extracellular_Viral_Load_3/links/0912f4fbe56f10cf4e000000.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:europepmc.org:2560009","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3421589","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320334506","display_name":"Canadian Institutes of Health Research","ror":"https://ror.org/01gavpb45"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W1542320852","https://openalex.org/W1659719610","https://openalex.org/W1772934320","https://openalex.org/W1793476185","https://openalex.org/W1946734657","https://openalex.org/W1966261980","https://openalex.org/W1976624282","https://openalex.org/W1990353949","https://openalex.org/W1993270674","https://openalex.org/W1999048558","https://openalex.org/W2007021820","https://openalex.org/W2008075115","https://openalex.org/W2012139740","https://openalex.org/W2012325453","https://openalex.org/W2020096299","https://openalex.org/W2027458871","https://openalex.org/W2027738518","https://openalex.org/W2030572778","https://openalex.org/W2032134000","https://openalex.org/W2035813371","https://openalex.org/W2044874413","https://openalex.org/W2051240607","https://openalex.org/W2061536465","https://openalex.org/W2064502505","https://openalex.org/W2065190721","https://openalex.org/W2069407559","https://openalex.org/W2070990188","https://openalex.org/W2089904127","https://openalex.org/W2090611257","https://openalex.org/W2093009072","https://openalex.org/W2103153013","https://openalex.org/W2112419344","https://openalex.org/W2117025121","https://openalex.org/W2117032763","https://openalex.org/W2125955093","https://openalex.org/W2126255146","https://openalex.org/W2133649749","https://openalex.org/W2138294993","https://openalex.org/W2146478787","https://openalex.org/W2150357065","https://openalex.org/W2156197349","https://openalex.org/W2160230582","https://openalex.org/W2168736565","https://openalex.org/W2331385561"],"related_works":["https://openalex.org/W2343381749","https://openalex.org/W2008734270","https://openalex.org/W2150430206","https://openalex.org/W7047692694","https://openalex.org/W1998268937","https://openalex.org/W2736565360","https://openalex.org/W2318462197","https://openalex.org/W2070546303","https://openalex.org/W2061467475","https://openalex.org/W1122889353"],"abstract_inverted_index":{"HIV":[0],"entry":[1,47,103,142,175,191,206,214,233],"inhibitors,":[2],"such":[3],"as":[4,244],"maraviroc":[5],"(MVC),":[6],"prevent":[7],"cell-free":[8],"viruses":[9,44],"from":[10],"entering":[11],"the":[12,30,65,87,99,151,154,167,188,199,229],"cells.":[13,135],"In":[14],"clinical":[15,249],"trials,":[16],"patients":[17],"who":[18],"were":[19,28,117],"treated":[20,156],"with":[21,64,78,157,221],"MVC":[22],"often":[23],"displayed":[24],"viral":[25,34,58,106,137,169,185,240],"loads":[26],"that":[27,43,71,141,213],"above":[29],"limit":[31],"of":[32,67,89,92,127,148,190,231,248],"conventional":[33],"load":[35,59,138,170,186,241],"detection":[36],"compared":[37,61],"to":[38,52,62,122],"efavirenz-based":[39],"regimens.":[40],"We":[41,74,180],"hypothesize":[42],"blocked":[45],"by":[46,204],"inhibitors":[48,176,215,234],"may":[49,235],"be":[50,236],"redistributed":[51,128],"plasma,":[53],"where":[54],"they":[55],"artificially":[56],"increase":[57],"measurements":[60],"those":[63],"use":[66],"antiretroviral":[68],"drugs":[69],"(ARVs)":[70],"act":[72],"intracellularly.":[73],"infected":[75],"PM-1":[76],"cells":[77,144,155],"CCR5-tropic":[79],"HIV-1":[80,84,130],"BaL":[81],"or":[82],"CXCR4-tropic":[83],"NL4-3":[85],"in":[86,150,209],"presence":[88],"inhibitory":[90],"concentrations":[91],"efavirenz,":[93],"raltegravir,":[94],"enfuvirtide,":[95],"maraviroc,":[96],"and":[97,112,187],"AMD3100,":[98],"latter":[100],"three":[101],"being":[102],"inhibitors.":[104],"Supernatant":[105],"load,":[107],"reverse":[108],"transcriptase":[109],"enzyme":[110],"activity,":[111],"intracellular":[113,222],"nucleic":[114],"acid":[115],"levels":[116,147],"measured":[118],"at":[119,160],"times":[120],"up":[121],"24":[123,165],"h":[124,162],"postinfection.":[125,163],"Infectivity":[126],"dual-tropic":[129],"was":[131,171,196],"assessed":[132],"using":[133],"TZM-bl":[134],"Extracellular":[136],"analysis":[139],"revealed":[140],"inhibitor-treated":[143],"had":[145],"higher":[146,173],"virus":[149,194],"supernatant":[152,168],"than":[153,177],"other":[158,178],"ARVs":[159],"8":[161],"By":[164],"h,":[166],"still":[172],"for":[174],"ARVs.":[179],"observed":[181],"a":[182,217,245],"correlation":[183],"between":[184],"step":[189],"inhibition.":[192,207],"Dual-tropic":[193],"infectivity":[195],"undiminished":[197],"utilizing":[198],"CCR5":[200],"coreceptor":[201],"following":[202],"redistribution":[203,218],"CXCR4":[205],"This":[208],"vitro":[210],"model":[211],"indicates":[212],"exhibit":[216],"effect":[219],"unseen":[220],"ARV":[223],"drugs.":[224],"Based":[225],"on":[226],"these":[227],"results,":[228],"effectiveness":[230],"some":[232],"underestimated":[237],"if":[238],"plasma":[239],"is":[242],"used":[243],"sole":[246],"indicator":[247],"success.":[250]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}